AIM: The authors analyzed in a retrospective manner the prognostic significance of @entity876 and @entity7465 expression, DNA ploidy, S-phase fraction (SPF), and traditional clinical and pathological prognostic factors in @entity1 with uterine @entity1822 . MATERIAL: Forty-nine @entity1 were diagnosed with @entity1822 (25 stage I, 4 stage II, 8 stage III, and 12 stage IV). DNA flow cytometric analysis and immunohistochemical staining for @entity876 and @entity7465 were performed on @entity982 -embedded archival tissue from the uterine @entity5 . RESULTS: Of the 49 @entity1 , 35 (71%) died of disease and 2 died of intercurrent disease. The 5-year survival rate was 33%. FIGO surgical stage, DNA ploidy, SPF, mitotic index, cellular atypia, and @entity5 grade obtained significance (P < 0.05) in a univariate survival analysis of the @entity1822 . In a multivariate analysis with survival as the end point, stage was found to be the most important factor (P = 0.007); DNA ploidy (P = 0. 045) and SPF (P = 0.041) also had independent prognostic significance. For FIGO stage I @entity5 , DNA ploidy (P = 0.04) and @entity5 grade (P = 0.01) were statistically significant in a univariate analysis, while only grade had independent prognostic significance (P = 0.01) in a multivariate analysis. In a univariate analysis including only FIGO stage I and II @entity5 with disease-free survival as the end point, @entity876 overexpression (P = 0.0016), DNA ploidy (P = 0.042), and @entity5 grade (P = 0.008) obtained significance. In a multivariate analysis, only @entity876 had independent statistical significance (P = 0.01). All @entity876 immunopositive stage I-II @entity5 recurred within 28 months from diagnosis. CONCLUSION: This study found that stage represents the most important prognostic factor for uterine @entity1822 . DNA ploidy and SPF had independent prognostic value. DNA flow cytometry is useful in gaining additional prognostic information. In stage I @entity1 , @entity5 grade gives significant information regarding clinical outcome. In addition, @entity876 overexpression may predict a higher risk of recurrence in early stage @entity1822 .

XXXX : A clinicopathologic, DNA flow cytometric, @entity876 , and @entity7465 analysis of 49 cases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7465 :: ('4193', 'Gene') :: ['mdm-2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['uterine leiomyosarcoma', 'leiomyosarcomas'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']
@entity1822 :: (MESH:D007890,Disease) :: ['Leiomyosarcoma of the uterus']
